KCNJ2 and nonpapillary renal cell carcinoma: Finally, it would be of interest to explore the potential of combining KCNJ2 expression with other genetic and molecular markers to predict patient responses to targeted therapies and immunotherapies, ultimately guiding personalized treatment approaches for ccRCC patients.